Recombinant AAV is a powerful vector for gene delivery—but its full potential is held back by the limitations of plasmid DNA. Touchlight’s whitepaper explores how dbDNA™, a synthetic, enzymatically produced…
Read More
As gene therapy accelerates, the demand for scalable viral vector manufacturing has never been greater. Yet traditional plasmid DNA (pDNA) remains a limiting factor, slowed by scalability challenges, bacterial contamination…
Read More
Sarah Moore In this white paper, authored by Dr Sarah Moore, Head of Gene Therapy Discovery, Touchlight, we discuss major challenges and present approaches to improve overall functional titre, through…
Read More
